Stuart A. Forman, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, GABA-A | 55 | 2023 | 627 | 10.170 |
Why?
|
| Etomidate | 33 | 2023 | 190 | 7.770 |
Why?
|
| Anesthetics | 21 | 2023 | 538 | 4.660 |
Why?
|
| Anesthetics, General | 18 | 2020 | 152 | 3.940 |
Why?
|
| Anesthetics, Intravenous | 12 | 2021 | 417 | 3.750 |
Why?
|
| Receptors, Nicotinic | 31 | 2014 | 497 | 3.100 |
Why?
|
| Propofol | 12 | 2023 | 628 | 2.450 |
Why?
|
| Ion Channel Gating | 21 | 2018 | 437 | 2.220 |
Why?
|
| GABA Agonists | 11 | 2018 | 111 | 2.080 |
Why?
|
| Hypnotics and Sedatives | 12 | 2022 | 1158 | 2.080 |
Why?
|
| Cysteine | 6 | 2023 | 873 | 1.950 |
Why?
|
| Xenopus laevis | 30 | 2021 | 956 | 1.850 |
Why?
|
| Protein Subunits | 12 | 2019 | 960 | 1.850 |
Why?
|
| Receptors, GABA | 6 | 2022 | 288 | 1.820 |
Why?
|
| Binding Sites | 25 | 2023 | 6115 | 1.500 |
Why?
|
| Nicotinic Antagonists | 9 | 2012 | 96 | 1.400 |
Why?
|
| GABA-A Receptor Agonists | 6 | 2014 | 84 | 1.330 |
Why?
|
| Anesthesia, General | 6 | 2020 | 1164 | 1.230 |
Why?
|
| Patch-Clamp Techniques | 22 | 2018 | 963 | 1.180 |
Why?
|
| Oocytes | 24 | 2018 | 1186 | 1.170 |
Why?
|
| gamma-Aminobutyric Acid | 20 | 2023 | 1123 | 1.170 |
Why?
|
| Locomotion | 2 | 2019 | 378 | 1.140 |
Why?
|
| Electrophysiology | 12 | 2022 | 1309 | 1.110 |
Why?
|
| Allosteric Regulation | 20 | 2020 | 408 | 1.100 |
Why?
|
| Pregnanediones | 4 | 2018 | 11 | 1.080 |
Why?
|
| Xenopus | 17 | 2020 | 712 | 1.030 |
Why?
|
| Photoaffinity Labels | 8 | 2018 | 86 | 1.000 |
Why?
|
| Anesthetics, Inhalation | 7 | 2006 | 571 | 0.930 |
Why?
|
| Ion Channels | 14 | 2010 | 1056 | 0.860 |
Why?
|
| Hypnosis | 1 | 2022 | 82 | 0.820 |
Why?
|
| Midazolam | 2 | 2022 | 270 | 0.800 |
Why?
|
| Mesylates | 1 | 2021 | 36 | 0.790 |
Why?
|
| Tryptophan | 2 | 2016 | 478 | 0.770 |
Why?
|
| Mutagenesis, Site-Directed | 9 | 2018 | 1723 | 0.740 |
Why?
|
| Glycopyrrolate | 1 | 2020 | 33 | 0.730 |
Why?
|
| Genetic Techniques | 2 | 2013 | 435 | 0.730 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 462 | 0.730 |
Why?
|
| Neostigmine | 1 | 2020 | 69 | 0.720 |
Why?
|
| Larva | 9 | 2018 | 517 | 0.710 |
Why?
|
| Muscarinic Antagonists | 1 | 2020 | 137 | 0.690 |
Why?
|
| Pharmacogenetics | 2 | 2022 | 676 | 0.680 |
Why?
|
| Isoflurane | 3 | 2020 | 381 | 0.680 |
Why?
|
| Reflex, Righting | 1 | 2018 | 18 | 0.670 |
Why?
|
| Amino Acid Substitution | 5 | 2016 | 1792 | 0.650 |
Why?
|
| Barbiturates | 4 | 2022 | 114 | 0.640 |
Why?
|
| Alkanes | 3 | 2003 | 44 | 0.640 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2020 | 239 | 0.640 |
Why?
|
| Bradycardia | 1 | 2020 | 305 | 0.630 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2017 | 24 | 0.620 |
Why?
|
| Animals | 84 | 2022 | 168561 | 0.600 |
Why?
|
| Tachycardia | 1 | 2020 | 620 | 0.600 |
Why?
|
| Pentobarbital | 2 | 2016 | 155 | 0.560 |
Why?
|
| Anesthesia Department, Hospital | 1 | 2014 | 68 | 0.490 |
Why?
|
| Protein Structure, Secondary | 5 | 2018 | 1245 | 0.490 |
Why?
|
| 4-Chloromercuribenzenesulfonate | 1 | 2013 | 7 | 0.480 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 1368 | 0.460 |
Why?
|
| Ethanol | 6 | 2000 | 1337 | 0.450 |
Why?
|
| Torpedo | 17 | 2011 | 169 | 0.440 |
Why?
|
| Diazomethane | 4 | 2018 | 36 | 0.440 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 944 | 0.430 |
Why?
|
| Diazepam | 3 | 2022 | 205 | 0.400 |
Why?
|
| Cysteine Loop Ligand-Gated Ion Channel Receptors | 1 | 2011 | 4 | 0.400 |
Why?
|
| Octanols | 3 | 2007 | 27 | 0.390 |
Why?
|
| HEK293 Cells | 10 | 2020 | 4200 | 0.380 |
Why?
|
| Interleukin-2 | 1 | 2017 | 1887 | 0.370 |
Why?
|
| Mutation, Missense | 3 | 2014 | 2556 | 0.360 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 1873 | 0.350 |
Why?
|
| Mutation | 17 | 2023 | 29717 | 0.350 |
Why?
|
| Models, Molecular | 6 | 2020 | 5454 | 0.350 |
Why?
|
| Zebrafish | 7 | 2022 | 2990 | 0.340 |
Why?
|
| Azirines | 3 | 2012 | 30 | 0.340 |
Why?
|
| Mephobarbital | 2 | 2022 | 7 | 0.330 |
Why?
|
| Heart Rate | 1 | 2020 | 4091 | 0.330 |
Why?
|
| Protein Structure, Tertiary | 6 | 2016 | 3847 | 0.320 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 2133 | 0.320 |
Why?
|
| Pyrroles | 2 | 2012 | 1143 | 0.320 |
Why?
|
| Biomedical Research | 2 | 2014 | 3306 | 0.320 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2012 | 895 | 0.310 |
Why?
|
| Schools, Medical | 1 | 2014 | 878 | 0.310 |
Why?
|
| Anesthesiology | 2 | 2014 | 1043 | 0.290 |
Why?
|
| Allosteric Site | 3 | 2014 | 103 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2020 | 10943 | 0.290 |
Why?
|
| Benzodiazepines | 3 | 2021 | 1101 | 0.290 |
Why?
|
| Alcohols | 5 | 1997 | 92 | 0.280 |
Why?
|
| Lymphocyte Activation | 1 | 2017 | 5519 | 0.280 |
Why?
|
| GABA Antagonists | 2 | 2003 | 128 | 0.270 |
Why?
|
| GABA Agents | 2 | 2015 | 42 | 0.270 |
Why?
|
| Unconsciousness | 1 | 2008 | 262 | 0.270 |
Why?
|
| Structure-Activity Relationship | 12 | 2020 | 3133 | 0.260 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 2217 | 0.260 |
Why?
|
| Electrophysiological Phenomena | 2 | 2018 | 316 | 0.250 |
Why?
|
| Acetylcholine | 8 | 1999 | 621 | 0.250 |
Why?
|
| DNA, Complementary | 5 | 2009 | 2049 | 0.230 |
Why?
|
| Kinetics | 12 | 2007 | 6474 | 0.220 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2002 | 20 | 0.220 |
Why?
|
| Muscles | 1 | 2007 | 1617 | 0.210 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 3800 | 0.210 |
Why?
|
| Consciousness | 1 | 2008 | 571 | 0.210 |
Why?
|
| 1-Butanol | 1 | 2001 | 13 | 0.200 |
Why?
|
| Flumazenil | 4 | 2021 | 85 | 0.200 |
Why?
|
| Humans | 60 | 2022 | 742088 | 0.200 |
Why?
|
| Hexanols | 1 | 2000 | 6 | 0.200 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 1372 | 0.200 |
Why?
|
| Blood Proteins | 1 | 2006 | 1122 | 0.200 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 3 | 2010 | 43 | 0.200 |
Why?
|
| Cell Line | 7 | 2017 | 15994 | 0.200 |
Why?
|
| Female | 31 | 2021 | 379592 | 0.200 |
Why?
|
| Photic Stimulation | 1 | 2008 | 2027 | 0.190 |
Why?
|
| Animals, Genetically Modified | 2 | 2019 | 1546 | 0.190 |
Why?
|
| Membrane Potentials | 5 | 2015 | 1135 | 0.190 |
Why?
|
| Protein Binding | 6 | 2014 | 9387 | 0.190 |
Why?
|
| Plasmids | 3 | 2012 | 2305 | 0.190 |
Why?
|
| Adrenal Cortex | 2 | 2011 | 139 | 0.180 |
Why?
|
| Amnesia | 1 | 2022 | 244 | 0.180 |
Why?
|
| Ligands | 10 | 2017 | 3293 | 0.180 |
Why?
|
| Affinity Labels | 1 | 1999 | 109 | 0.180 |
Why?
|
| Central Nervous System Depressants | 1 | 2000 | 167 | 0.170 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2012 | 407 | 0.160 |
Why?
|
| Models, Biological | 5 | 2012 | 9581 | 0.160 |
Why?
|
| Nicotinic Agonists | 3 | 2014 | 271 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2019 | 14554 | 0.160 |
Why?
|
| Synapses | 3 | 2017 | 1724 | 0.150 |
Why?
|
| Rats | 6 | 2018 | 24265 | 0.150 |
Why?
|
| Conscious Sedation | 1 | 2022 | 528 | 0.150 |
Why?
|
| Caenorhabditis elegans | 1 | 2006 | 1416 | 0.150 |
Why?
|
| Receptors, Cholinergic | 2 | 1989 | 238 | 0.150 |
Why?
|
| Cattle | 5 | 2012 | 3923 | 0.140 |
Why?
|
| Amino Acid Sequence | 6 | 2014 | 13814 | 0.140 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 392 | 0.140 |
Why?
|
| Molecular Sequence Data | 7 | 2014 | 18112 | 0.140 |
Why?
|
| Light | 3 | 2012 | 1374 | 0.140 |
Why?
|
| Mice | 16 | 2019 | 81045 | 0.140 |
Why?
|
| Convulsants | 1 | 2015 | 70 | 0.130 |
Why?
|
| Central Nervous System | 1 | 2003 | 1354 | 0.130 |
Why?
|
| Brain | 6 | 2014 | 26343 | 0.130 |
Why?
|
| Phenobarbital | 1 | 2015 | 192 | 0.130 |
Why?
|
| Neurotransmitter Agents | 1 | 2018 | 647 | 0.130 |
Why?
|
| Boston | 2 | 2020 | 9305 | 0.120 |
Why?
|
| Drug Partial Agonism | 1 | 2014 | 25 | 0.120 |
Why?
|
| Cell Membrane | 5 | 2014 | 3744 | 0.120 |
Why?
|
| Reflex | 3 | 2011 | 365 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2017 | 1341 | 0.120 |
Why?
|
| Carbachol | 5 | 1993 | 226 | 0.110 |
Why?
|
| Death, Sudden | 1 | 2015 | 298 | 0.110 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 6608 | 0.110 |
Why?
|
| Pulmonary Ventilation | 1 | 2015 | 372 | 0.110 |
Why?
|
| GABA-A Receptor Antagonists | 2 | 2003 | 62 | 0.110 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1875 | 0.110 |
Why?
|
| GABA Modulators | 2 | 2020 | 107 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2022 | 5062 | 0.110 |
Why?
|
| Erythrocyte Membrane | 2 | 1985 | 442 | 0.110 |
Why?
|
| Point Mutation | 1 | 2018 | 1624 | 0.110 |
Why?
|
| Azo Compounds | 1 | 2012 | 113 | 0.110 |
Why?
|
| Transfection | 4 | 2010 | 5892 | 0.100 |
Why?
|
| Synaptic Membranes | 3 | 1991 | 87 | 0.100 |
Why?
|
| Molecular Structure | 4 | 2020 | 1907 | 0.100 |
Why?
|
| Mice, SCID | 1 | 2017 | 2715 | 0.100 |
Why?
|
| Carboxylic Acids | 1 | 2011 | 99 | 0.100 |
Why?
|
| Faculty | 1 | 2014 | 383 | 0.100 |
Why?
|
| Plant Oils | 1 | 2012 | 202 | 0.100 |
Why?
|
| Microelectrodes | 2 | 2003 | 303 | 0.100 |
Why?
|
| Fluoxetine | 1 | 2015 | 749 | 0.100 |
Why?
|
| Receptors, Adrenergic | 1 | 2011 | 155 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2018 | 8300 | 0.090 |
Why?
|
| Anesthesia, Intravenous | 1 | 2011 | 130 | 0.090 |
Why?
|
| Tetracycline | 1 | 2010 | 214 | 0.090 |
Why?
|
| Epilepsy | 2 | 2015 | 3301 | 0.090 |
Why?
|
| Adrenal Cortex Diseases | 1 | 2009 | 13 | 0.090 |
Why?
|
| Cell Division | 1 | 2017 | 4564 | 0.090 |
Why?
|
| Chemistry, Physical | 2 | 2002 | 156 | 0.090 |
Why?
|
| Solubility | 4 | 2012 | 1083 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3557 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2006 | 7873 | 0.090 |
Why?
|
| Chemical Phenomena | 2 | 2002 | 517 | 0.090 |
Why?
|
| Procaine | 1 | 1989 | 60 | 0.090 |
Why?
|
| Pulmonary Alveoli | 2 | 2003 | 675 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2014 | 13029 | 0.080 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins | 1 | 2008 | 7 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 1255 | 0.080 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIc | 1 | 2008 | 15 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2017 | 3770 | 0.080 |
Why?
|
| Shaw Potassium Channels | 1 | 2008 | 19 | 0.080 |
Why?
|
| Hypercalciuria | 1 | 2008 | 31 | 0.080 |
Why?
|
| Rubidium | 6 | 1993 | 133 | 0.080 |
Why?
|
| Drug Design | 2 | 2010 | 1078 | 0.080 |
Why?
|
| Membranes | 3 | 2001 | 173 | 0.080 |
Why?
|
| Threonine | 1 | 2008 | 279 | 0.080 |
Why?
|
| Chloride Channels | 1 | 2008 | 225 | 0.070 |
Why?
|
| Algorithms | 5 | 2009 | 13853 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9735 | 0.070 |
Why?
|
| Models, Animal | 2 | 2020 | 2170 | 0.070 |
Why?
|
| Binding, Competitive | 3 | 2020 | 1159 | 0.070 |
Why?
|
| Microinjections | 1 | 2007 | 326 | 0.070 |
Why?
|
| Photochemical Processes | 2 | 2020 | 84 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2007 | 459 | 0.070 |
Why?
|
| Stereoisomerism | 5 | 2012 | 625 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2014 | 2739 | 0.070 |
Why?
|
| Benzophenones | 1 | 2006 | 57 | 0.070 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 545 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 1199 | 0.070 |
Why?
|
| Electric Organ | 4 | 1999 | 54 | 0.070 |
Why?
|
| Hemodynamics | 3 | 2011 | 4197 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2015 | 1914 | 0.070 |
Why?
|
| Steroids | 1 | 2011 | 931 | 0.070 |
Why?
|
| Choline | 1 | 1987 | 487 | 0.070 |
Why?
|
| Halothane | 1 | 1985 | 206 | 0.070 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 1985 | 153 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2011 | 1847 | 0.060 |
Why?
|
| Ultraviolet Rays | 2 | 2007 | 1059 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2008 | 1791 | 0.060 |
Why?
|
| Registries | 1 | 2020 | 8077 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2010 | 941 | 0.060 |
Why?
|
| Butanes | 1 | 2003 | 7 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2008 | 1227 | 0.060 |
Why?
|
| Carbolines | 1 | 2005 | 265 | 0.060 |
Why?
|
| Serotonin | 1 | 2007 | 1024 | 0.060 |
Why?
|
| Phloretin | 1 | 1982 | 17 | 0.060 |
Why?
|
| Picrotoxin | 1 | 2002 | 65 | 0.060 |
Why?
|
| Gene Expression | 2 | 2018 | 7790 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2010 | 1057 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2007 | 1458 | 0.050 |
Why?
|
| Electroencephalography | 2 | 2008 | 6142 | 0.050 |
Why?
|
| Neurons | 3 | 2014 | 9325 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2005 | 981 | 0.050 |
Why?
|
| Cyclopropanes | 1 | 2003 | 416 | 0.050 |
Why?
|
| Drug Antagonism | 1 | 2020 | 50 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 16665 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 4465 | 0.050 |
Why?
|
| Biotransformation | 2 | 2011 | 168 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 1985 | 5019 | 0.050 |
Why?
|
| Dopamine | 1 | 2007 | 1589 | 0.050 |
Why?
|
| Ion Transport | 1 | 2001 | 320 | 0.040 |
Why?
|
| Isomerism | 2 | 2015 | 201 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 2714 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 40054 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 4933 | 0.040 |
Why?
|
| Male | 7 | 2020 | 349538 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2008 | 2257 | 0.040 |
Why?
|
| Amino Acids | 2 | 2005 | 1727 | 0.040 |
Why?
|
| Anesthesia | 1 | 2010 | 1548 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 23320 | 0.040 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 449 | 0.040 |
Why?
|
| DNA | 1 | 2012 | 7289 | 0.040 |
Why?
|
| Receptors, Parathyroid Hormone | 1 | 1998 | 332 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2012 | 5100 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2005 | 4013 | 0.040 |
Why?
|
| Imidazoles | 1 | 2003 | 1205 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2001 | 19223 | 0.030 |
Why?
|
| Serum Albumin | 1 | 1998 | 674 | 0.030 |
Why?
|
| Postural Balance | 2 | 2010 | 620 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 72145 | 0.030 |
Why?
|
| Ketamine | 1 | 2020 | 499 | 0.030 |
Why?
|
| Muscimol | 1 | 2013 | 69 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2015 | 642 | 0.030 |
Why?
|
| Rubidium Radioisotopes | 2 | 1993 | 85 | 0.030 |
Why?
|
| Anion Transport Proteins | 2 | 1985 | 142 | 0.030 |
Why?
|
| Xenopus Proteins | 1 | 2016 | 433 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2020 | 62966 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1982 | 2452 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 2011 | 1825 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7153 | 0.030 |
Why?
|
| Kidney | 2 | 2008 | 7167 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 77098 | 0.020 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 1 | 2010 | 18 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2010 | 379 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2003 | 3439 | 0.020 |
Why?
|
| Esterases | 1 | 2009 | 95 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 549 | 0.020 |
Why?
|
| Computer Simulation | 2 | 2016 | 6191 | 0.020 |
Why?
|
| Alzheimer Disease | 1 | 2010 | 7988 | 0.020 |
Why?
|
| Bungarotoxins | 1 | 1988 | 46 | 0.020 |
Why?
|
| Opossums | 1 | 2008 | 106 | 0.020 |
Why?
|
| Tritium | 1 | 2009 | 746 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 21596 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 658 | 0.020 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 162 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 1802 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 1814 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 162944 | 0.020 |
Why?
|
| Isoflurophate | 1 | 1987 | 36 | 0.020 |
Why?
|
| Mathematics | 1 | 1989 | 727 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15244 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1987 | 165 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 213712 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1987 | 205 | 0.020 |
Why?
|
| Exocytosis | 1 | 2008 | 353 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 213127 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 817 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 1989 | 3584 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 898 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 2161 | 0.020 |
Why?
|
| Lidocaine | 1 | 2009 | 542 | 0.020 |
Why?
|
| Aziridines | 1 | 2005 | 21 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 1407 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2010 | 4322 | 0.020 |
Why?
|
| Phosphates | 1 | 2008 | 786 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 2471 | 0.020 |
Why?
|
| Serine | 1 | 2008 | 828 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 18006 | 0.010 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1982 | 34 | 0.010 |
Why?
|
| Alleles | 2 | 2008 | 6931 | 0.010 |
Why?
|
| Sodium | 1 | 2008 | 1627 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2007 | 1770 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1995 | 4983 | 0.010 |
Why?
|
| Nicotine | 1 | 1987 | 677 | 0.010 |
Why?
|
| Haplotypes | 1 | 2008 | 2781 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 1030 | 0.010 |
Why?
|
| Reaction Time | 1 | 2007 | 2092 | 0.010 |
Why?
|
| Biological Transport | 1 | 1985 | 2119 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 14720 | 0.010 |
Why?
|
| Rana pipiens | 1 | 1999 | 65 | 0.010 |
Why?
|
| Cerebral Cortex | 2 | 2010 | 5705 | 0.010 |
Why?
|
| Aging | 1 | 1998 | 8626 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1982 | 2552 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 8436 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 12797 | 0.010 |
Why?
|
| Receptor, Parathyroid Hormone, Type 1 | 1 | 1998 | 307 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 1160 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2010 | 4030 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1982 | 1915 | 0.010 |
Why?
|
| Embryo, Nonmammalian | 1 | 1998 | 894 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1995 | 11690 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 1950 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1993 | 326 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1998 | 2837 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13256 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 2027 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 15494 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1995 | 10248 | 0.000 |
Why?
|
| Heart | 1 | 1995 | 4462 | 0.000 |
Why?
|
| Exercise | 1 | 1995 | 5611 | 0.000 |
Why?
|
| Prognosis | 1 | 1995 | 29010 | 0.000 |
Why?
|